Classification of early tuberculosis states to guide research for improved care and prevention: an international Delphi consensus exercise

Abstract

The current active-latent paradigm of tuberculosis largely neglects the documented spectrum of disease. Inconsistency with regard to definitions, terminology, and diagnostic criteria for different tuberculosis states has limited the progress in research and product development that are needed to achieve tuberculosis elimination. We aimed to develop a new framework of classification for tuberculosis that accommodates key disease states but is sufficiently simple to support pragmatic research and implementation. Through an international Delphi exercise that involved 71 participants representing a wide range of disciplines, sectors, income settings, and geographies, consensus was reached on a set of conceptual states, related terminology, and research gaps. The International Consensus for Early TB (ICE-TB) framework distinguishes disease from infection by the presence of macroscopic pathology and defines two subclinical and two clinical tuberculosis states on the basis of reported symptoms or signs of tuberculosis, further differentiated by likely infectiousness. The presence of viable Mycobacterium tuberculosis and an associated host response are prerequisites for all states of infection and disease. Our framework provides a clear direction for tuberculosis research, which will, in time, improve tuberculosis clinical care and elimination policies.

References 67

1. 1.

   Comas I, Coscolla M, Luo T, Borrell S, Holt KE, Kato-Maeda M, et al. Out-of-Africa migration and Neolithic coexpansion of Mycobacterium tuberculosis with modern humans. Nat Genet. 2013;45:1176-82.

   Not in our library10.1038/ng.2744 (opens in a new tab)

2. 2.

   Lange C, Aaby P, Behr MA, Donald PR, Kaufmann SHE, Netea MG, et al. 100 years of Mycobacterium bovis bacille Calmette-Guérin. Lancet Infect Dis. 2022;22:e2-12.

   Not in our library10.1016/s1473-3099(21)00403-5 (opens in a new tab)

3. 3.

   Streptomycin Treatment of Pulmonary Tuberculosis: A Medical Research Council Investigation. Br Med J. 1948;2:769-82.

   Not in our library10.1136/bmj.2.4582.769 (opens in a new tab)

4. 4.

   Gothi GD. Natural History of Tuberculosis. Indian J Tuberc. 1978;25:13.

   Not in our library

5. 5.

   Diagnostic Standards and Classification of Tuberculosis. 1940.

   Not in our library

6. 6.

   Weg JG. Diagnostic standards of tuberculosis--revised. JAMA. 1976;235:1329-30.

   Not in our library10.1001/jama.235.13.1329 (opens in a new tab)

7. 7.

   Long ER, Hopkins FD. History of Diagnostic Standards and Classification of Tuberculosis of the National Tuberculosis Association. Am Rev Tuberc. 1952;65:494-504.

   Not in our library10.1164/art.1952.65.4.494 (opens in a new tab)

8. 8.

   Communicable Diseases Cluster. What is DOTS?: a guide to understanding the WHO-recommended TB control strategy known as DOTS. 1999.

   Not in our library

9. 9.

   Raviglione M, Marais B, Floyd K, Lonnroth K, Getahun H, Migliori GB, et al. Scaling up interventions to achieve global tuberculosis control: progress and new developments. Lancet. 2012;379:1902-13.

   Not in our library10.1016/s0140-6736(12)60727-2 (opens in a new tab)

10. 10.

    Mandal S, Chadha VK, Laxminarayan R, Arinaminpathy N. Counting the lives saved by DOTS in India: a model-based approach. BMC Medicine. 2017;15.

    Not in our library10.1186/s12916-017-0809-5 (opens in a new tab)

11. 11.

    Floyd K, Glaziou P, Houben RMGJ, Sumner T, White RG, Raviglione M. Global tuberculosis targets and milestones set for 2016–2035: definition and rationale. Int J Tuberc Lung Dis. 2018;22:723-30.

    Not in our library10.5588/ijtld.17.0835 (opens in a new tab)

12. 12.

    Lonnroth K, Migliori GB, Abubakar I, D’Ambrosio L, de Vries G, Diel R, et al. Towards tuberculosis elimination: an action framework for low-incidence countries. Eur Respir J. 2015;45:928-52.

    Not in our library10.1183/09031936.00214014 (opens in a new tab)

13. 13.

    Migliori GB, Dowdy D, Denholm JT, D’Ambrosio L, Centis R. The path to tuberculosis elimination: a renewed vision. Eur Respir J. 2023;61:2300499.

    Not in our library10.1183/13993003.00499-2023 (opens in a new tab)

14. 14.

    Frascella B, Richards AS, Sossen B, Emery JC, Odone A, Law I, et al. Subclinical Tuberculosis Disease—A Review and Analysis of Prevalence Surveys to Inform Definitions, Burden, Associations, and Screening Methodology. Clinical Infectious Diseases. 2021;73:e830-41.

    Not in our library10.1093/cid/ciaa1402 (opens in a new tab)

15. 15.

    Richards AS, Sossen B, Emery JC, Horton KC, Heinsohn T, Frascella B, et al. Quantifying progression and regression across the spectrum of pulmonary tuberculosis: a data synthesis study. The Lancet Global Health. 2023.

    Not in our library10.1016/s2214-109x(23)00082-7 (opens in a new tab)

16. 16.

    Kendall EA, Shrestha S, Dowdy DW. The Epidemiological Importance of Subclinical Tuberculosis. A Critical Reappraisal. Am J Respir Crit Care Med. 2021;203:168-74.

    Not in our library10.1164/rccm.202006-2394pp (opens in a new tab)

17. 17.

    Global tuberculosis report 2022. 2022.

    Not in our library

18. 18.

    Jonas DE, Riley SR, Lee LC, Coffey CP, Wang S-H, Asher GN, et al. Screening for Latent Tuberculosis Infection in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2023;329:1495-509.

    Not in our library10.1001/jama.2023.3954 (opens in a new tab)

19. 19.

    Drain PK, Bajema KL, Dowdy D, Dheda K, Naidoo K, Schumacher SG, et al. Incipient and Subclinical Tuberculosis: a Clinical Review of Early Stages and Progression of Infection. Clinical Microbiology Reviews. 2018;31:24.

    Not in our library10.1128/cmr.00021-18 (opens in a new tab)

20. 20.

    Barry CE, Boshoff HI, Dartois V, Dick T, Ehrt S, Flynn J, et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Mic. 2009;7:845-55.

    Not in our library10.1038/nrmicro2236 (opens in a new tab)

21. 21.

    Zaidi SM, Coussens A, Kredo T, Seddon J, Warner D, Houben RMGJ, et al. Beyond latent and active: a scoping review of conceptual frameworks and diagnostic criteria for tuberculosis. 2023;2023.07.05.23292171.

    Not in our library10.1101/2023.07.05.23292171 (opens in a new tab)

22. 22.
    Patient outcomes associated with post-tuberculosis lung damage in Malawi: a prospective cohort study · 2020

    No notice
23. 23.

    Sossen B, Richards AS, Heinsohn T, Frascella B, Balzarini F, Oradini-Alacreu A, et al. The natural history of untreated pulmonary tuberculosis in adults: a systematic review and meta-analysis. The Lancet Respiratory Medicine. 2023.

    Not in our library10.1016/s2213-2600(23)00097-8 (opens in a new tab)

24. 24.

    Esmail H, Coussens AK, Thienemann F, Sossen B, Mukasa S, Warwick J, et al. High resolution imaging and five-year tuberculosis contact outcomes. 2023;2023.07.03.23292111.

    Not in our library10.1101/2023.07.03.23292111 (opens in a new tab)

25. 25.
    Is Mycobacterium tuberculosis infection life long? · 2019

    No notice
26. 26.

    WHO consolidated guidelines on tuberculosis - Module 2: Systematic screening for tuberculosis disease. 2021.

    Not in our library

27. 27.

    Pai M, Behr M. Latent Mycobacterium tuberculosis Infection and Interferon-Gamma Release Assays. Microbiol Spectr. 2016;4.

    Not in our library10.1128/microbiolspec.tbtb2-0023-2016 (opens in a new tab)

28. 28.

    Menzies NA, Wolf E, Connors D, Bellerose M, Sbarra AN, Cohen T, et al. Progression from latent infection to active disease in dynamic tuberculosis transmission models: a systematic review of the validity of modelling assumptions. The Lancet Infectious Diseases. 2018.

    Not in our library10.1016/s1473-3099(18)30134-8 (opens in a new tab)

29. 29.

    Horton KC, Richards AS, Emery JC, Esmail H, Houben RMGJ. Re-evaluating progression and pathways following Mycobacteria tuberculosis infection within the spectrum of tuberculosis disease. 2022;2022.12.14.22283422.

    Not in our library10.1101/2022.12.14.22283422 (opens in a new tab)

30. 30.

    Fan W-C, Liu C-J, Hong Y-C, Feng J-Y, Su W-J, Chien S-H, et al. Long-term risk of tuberculosis in haematopoietic stem cell transplant recipients: a 10-year nationwide study. Int J Tuberc Lung Dis. 2015;19:58-64.

    Not in our library10.5588/ijtld.14.0301 (opens in a new tab)

31. 31.

    Lee H-J, Lee D-G, Choi S-M, Park SH, Cho S-Y, Choi J-K, et al. The demanding attention of tuberculosis in allogeneic hematopoietic stem cell transplantation recipients: High incidence compared with general population. PLoS One. 2017;12:e0173250.

    Not in our library10.1371/journal.pone.0173250 (opens in a new tab)

32. 32.
    The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling · 2016

    No notice
33. 33.

    A study of the characteristics and course of sputum smear-negative pulmonary tuberculosis. Tubercle. 1981;62:155-67.

    Not in our library10.1016/0041-3879(81)90001-5 (opens in a new tab)

34. 34.

    Zwyer M, Rutaihwa LK, Windels E, Hella J, Menardo F, Sasamalo M, et al. Back-to-Africa introductions of Mycobacterium tuberculosis as the main cause of tuberculosis in Dar es Salaam, Tanzania. PLOS Pathogens. 2023;19:e1010893.

    Not in our library10.1371/journal.ppat.1010893 (opens in a new tab)

35. 35.

    Dinkele R, Gessner S, McKerry A, Leonard B, Leukes J, Seldon R, et al. Aerosolization of Mycobacterium tuberculosis by Tidal Breathing. Am J Respir Crit Care Med. 2022.

    Not in our library10.1164/rccm.202110-2378oc (opens in a new tab)

36. 36.
    Exhaled Mycobacterium tuberculosis output and detection of subclinical disease by face-mask sampling: prospective observational studies · 2020

    No notice
37. 37.

    Emery JC, Dodd PJ, Banu S, Frascella B, Garden FL, Horton KC, et al. Estimating the contribution of subclinical tuberculosis disease to transmission – an individual patient data analysis from prevalence surveys. 2022;2022.06.09.22276188.

    Not in our library10.1101/2022.06.09.22276188 (opens in a new tab)

38. 38.
    High-resolution mapping of tuberculosis transmission: Whole genome sequencing and phylogenetic modelling of a cohort from Valencia Region, Spain. · 2019

    Not checked
39. 39.

    Ku C-C, MacPherson P, Khundi M, Nzawa R, Feasey HRA, Nliwasa M, et al. Estimated durations of asymptomatic, symptomatic, and care-seeking phases of tuberculosis disease. Epidemiology. 2021.

    Not in our library10.1101/2021.03.17.21253823 (opens in a new tab)

40. 40.

    Ryckman TS, Dowdy DW, Kendall EA. Infectious and clinical tuberculosis trajectories: Bayesian modeling with case finding implications. Proc Natl Acad Sci U S A. 2022;119:e2211045119.

    Not in our library10.1073/pnas.2211045119 (opens in a new tab)

41. 41.

    Marks GB, Nguyen NV, Nguyen PTB, Nguyen T-A, Nguyen HB, Tran KH, et al. Community-wide Screening for Tuberculosis in a High-Prevalence Setting. New England Journal of Medicine. 2019;381:1347-57.

    Not in our library10.1056/nejmoa1902129 (opens in a new tab)

42. 42.

    Onozaki I, Law I, Sismanidis C, Zignol M, Glaziou P, Floyd K. National tuberculosis prevalence surveys in Asia, 1990-2012: an overview of results and lessons learned. Trop Med Int Health. 2015;20:1128-45.

    Not in our library10.1111/tmi.12534 (opens in a new tab)

43. 43.

    Law I, Floyd K, African TB Prevalence Survey Group. National tuberculosis prevalence surveys in Africa, 2008-2016: an overview of results and lessons learned. Trop Med Int Health. 2020;25:1308-27.

    Not in our library10.1111/tmi.13485 (opens in a new tab)

44. 44.

    Marais S, Thwaites G, Schoeman JF, Török ME, Misra UK, Prasad K, et al. Tuberculous meningitis: a uniform case definition for use in clinical research. The Lancet Infectious Diseases. 2010;10:803-12.

    Not in our library10.1016/s1473-3099(10)70138-9 (opens in a new tab)

45. 45.

    MacLean EL, Kohli M, Köppel L, Schiller I, Sharma SK, Pai M, et al. Bayesian latent class analysis produced diagnostic accuracy estimates that were more interpretable than composite reference standards for extrapulmonary tuberculosis tests. Diagn Progn Res. 2022;6:11.

    Not in our library10.1186/s41512-022-00125-x (opens in a new tab)

46. 46.

    Kohli M, Schiller I, Dendukuri N, Dheda K, Denkinger CM, Schumacher SG, et al. Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance. Cochrane Database of Systematic Reviews. 2018.

    Not in our library10.1002/14651858.cd012768.pub2 (opens in a new tab)

47. 47.

    Mpande CAM, Musvosvi M, Rozot V, Mosito B, Reid TD, Schreuder C, et al. Antigen-Specific T-Cell Activation Distinguishes between Recent and Remote Tuberculosis Infection. Am J Respir Crit Care Med. 2021;203:1556-65.

    Not in our library10.1164/rccm.202007-2686oc (opens in a new tab)

48. 48.

    Hiza H, Hella J, Arbués A, Magani B, Sasamalo M, Gagneux S, et al. Case–control diagnostic accuracy study of a non-sputum CD38-based TAM-TB test from a single milliliter of blood. Sci Rep. 2021;11:13190.

    Not in our library10.1038/s41598-021-92596-z (opens in a new tab)

49. 49.

    Sutherland JS, van der Spuy G, Gindeh A, Thuong NTT, Namuganga A, Owolabi O, et al. Diagnostic Accuracy of the Cepheid 3-gene Host Response Fingerstick Blood Test in a Prospective, Multi-site Study: Interim Results. Clin Infect Dis. 2022;74:2136-41.

    Not in our library10.1093/cid/ciab839 (opens in a new tab)

50. 50.
    Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial · 2021

    No notice
51. 51.

    Esmail H, Lai RP, Lesosky M, Wilkinson KA, Graham CM, Coussens AK, et al. Characterization of progressive HIV-associated tuberculosis using 2-deoxy-2-[18F]fluoro-D-glucose positron emission and computed tomography. Nat Med. 2016;22:1090-3.

    Not in our library10.1038/nm.4161 (opens in a new tab)

52. 52.

    Khan RMN, Ahn Y-M, Marriner GA, Via LE, D’Hooge F, Lee SS, et al. Distributable, Metabolic PET Reporting of Tuberculosis. bioRxiv. 2023;2023.04.03.535218.

    Not in our library10.1101/2023.04.03.535218 (opens in a new tab)

53. 53.

    Rundell SR, Wagar ZL, Meints LM, Olson CD, O’Neill MK, Piligian BF, et al. Deoxyfluoro-d-trehalose (FDTre) analogues as potential PET probes for imaging mycobacterial infection. Org Biomol Chem. 2016;14:8598-609.

    Not in our library10.1039/c6ob01734g (opens in a new tab)

54. 54.

    Huang Z, LaCourse SM, Kay AW, Stern J, Escudero JN, Youngquist BM, et al. CRISPR detection of circulating cell-free Mycobacterium tuberculosis DNA in adults and children, including children with HIV: a molecular diagnostics study. Lancet Microbe. 2022;3:e482-92.

    Not in our library10.1016/s2666-5247(22)00087-8 (opens in a new tab)

55. 55.

    Nathavitharana RR, Garcia-Basteiro AL, Ruhwald M, Cobelens F, Theron G. Reimagining the status quo: How close are we to rapid sputum-free tuberculosis diagnostics for all? eBioMedicine. 2022.

    Not in our library10.1016/j.ebiom.2022.103939 (opens in a new tab)

56. 56.

    Savage HR, Rickman HM, Burke RM, Odland ML, Savio M, Ringwald B, et al. Accuracy of upper respiratory tract samples to diagnose Mycobacterium tuberculosis: a systematic review and meta-analysis. 2023;2022.11.28.22282827.

    Not in our library10.1101/2022.11.28.22282827 (opens in a new tab)

57. 57.
    The Infectiousness of Tuberculosis Patients Coinfected with HIV · 2008

    No notice
58. 58.

    Hill PC, Ota MO. Tuberculosis case-contact research in endemic tropical settings: design, conduct, and relevance to other infectious diseases. The Lancet Infectious Diseases. 2010;10:723-32.

    Not in our library10.1016/s1473-3099(10)70164-x (opens in a new tab)

59. 59.

    Khan PY, Crampin AC, Mzembe T, Koole O, Fielding KL, Kranzer K, et al. Does antiretroviral treatment increase the infectiousness of smear-positive pulmonary tuberculosis? Int J Tuberc Lung Dis. 2017;21:1147-54.

    Not in our library10.5588/ijtld.17.0162 (opens in a new tab)

60. 60.

    Behr MA, Warren SA, Salamon H, Hopewell PC, Ponce de Leon A, Daley CL, et al. Transmission of Mycobacterium tuberculosis from patients smear-negative for acid-fast bacilli. Lancet. 1999;353:444-9.

    Not in our library10.1016/s0140-6736(98)03406-0 (opens in a new tab)

61. 61.

    Tostmann A, Kik SV, Kalisvaart NA, Sebek MM, Verver S, Boeree MJ, et al. Tuberculosis transmission by patients with smear-negative pulmonary tuberculosis in a large cohort in the Netherlands. Clin Infect Dis. 2008;47:1135-42.

    Not in our library10.1086/591974 (opens in a new tab)

62. 62.

    Acuña-Villaorduña C, Fennelly KP, Jones-López EC. Aerosol Sampling Outperforms Sputum to Predict Mycobacterium tuberculosis Transmission. Clin Infect Dis. 2023;ciad372.

    Not in our library10.1093/cid/ciad372 (opens in a new tab)

63. 63.

    Dhana A, Hamada Y, Kengne AP, Kerkhoff AD, Rangaka MX, Kredo T, et al. Tuberculosis screening among ambulatory people living with HIV: a systematic review and individual participant data meta-analysis. The Lancet Infectious Diseases. 2021;S147330992100387X.

    Not in our library10.1016/s1473-3099(21)00387-x (opens in a new tab)

64. 64.

    Stuck L, van Haaster A-C, Kapata-Chanda P, Klinkenberg E, Kapata N, Cobelens F. How ‘subclinical’ is subclinical tuberculosis? An analysis of national prevalence survey data from Zambia. Clinical Infectious Diseases. 2022;ciab1050.

    Not in our library10.1093/cid/ciab1050 (opens in a new tab)

65. 65.
    The association of atherosclerotic cardiovascular disease and statin use with inflammation and treatment outcomes in tuberculosis · 2021

    Not checked
66. 66.

    Chen G-L, Guo L, Yang S, Ji D-M. Cancer risk in tuberculosis patients in a high endemic area. BMC Cancer. 2021;21:679.

    Not in our library10.1186/s12885-021-08391-6 (opens in a new tab)

67. 67.

    Esmail H, Macpherson L, Coussens AK, Houben RMGJ. Mind the gap – Managing tuberculosis across the disease spectrum. eBioMedicine. 2022.

    Not in our library10.1016/j.ebiom.2022.103928 (opens in a new tab)

Questions about this paper

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.